Ampli®cation or overexpression of the HER-2/neu gene in breast cancers is associated with aggressive behavior and resistance to therapeutic regimens. The molecular mechanisms that contribute to therapeutic resistance/ survival of HER-2/neu-overexpressing tumor cells have not been well de®ned. To determine if phosphatidylinositol 3-kinase/AKT signaling contributes to cell survival in HER-2/neu-positive breast cancers, we performed immunohistochemical analyses to evaluate expression of HER-2/neu and AKT in a series of 52 breast carcinomas. Elevated expression of HER-2/neu was found to correlate with overexpression of AKT2 protein and activation of AKT kinase. HER-2/neu-overexpressing breast cancer cell lines were resistant to apoptosis induced by UV treatment and hypoxia, which was suppressed in the presence of the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin, indicating a link between AKT activation and stress resistance in HER-2/neu-overexpressing cells. These observations suggest that AKT signaling augments resistance to stress-induced apoptosis in breast cancer cells overexpressing HER-2/neu.
Introduction
Receptor tyrosine kinases can be classi®ed into several groups on the basis of sequence similarity and distinct structural features. One of these groups includes the epidermal growth factor receptor family, which consists of erbB-1 (EGFR) (Carpenter, 1979) , erbB-2 (HER-2/ neu) (Coussens et al., 1985; Semba et al., 1985) , erbB-3 (HER-3) (Coussens et al., 1985; Kraus et al., 1989; Carraway and Cantley, 1994) , and erbB-4 (HER-4) (Plowman et al., 1993; Tzahar et al., 1994) . Overexpression of HER-2/neu occurs in *30% of human breast cancers and is associated with a poor prognosis, suggesting that it can be used as a target for anti-tumor agents (Slamon et al., 1987; Bacus et al., 1992 Bacus et al., , 1994b Hancock et al., 1991; Wright et al., 1992) . In addition, HER-2/neu overexpression is associated with resistance to systemic therapies and local radiation therapies (Alaoui-Jamali et al., 1997) . However, the molecular mechanism(s) responsible for this therapeutic resistance has not been identi®ed. The ability of trophic factors to promote survival after stress signals has been attributed, at least in part, to phosphatidylinositol 3-kinase (PI3K)/AKT signaling (Pettmann and Henderson, 1998) . Recent studies have demonstrated that AKT regulates cellular survival by phosphorylating downstream targets Bad, procaspase 9, Forkhead family of transcription factors, and the NFkB regulator, IKK (Kulik et al., 1997; Marte and Downward, 1997; Cardone et al., 1998; Datta et al., 1999) . In addition, the phosphatase PTEN is a tumor suppressor whose loss results in constitutive activation of AKT, which has been implicated in drug resistance (Marsh et al., 1998; Cantley and Neel, 1999; Datta et al., 1999) .
The growth factor Heregulin or Neu dierentiation factor (NDF) is a ligand that binds HER-3 and HER-4, leading to HER-2 activation through heterodimerization (Holmes et al., 1992; Tzahar et al., 1994; Klapper et al., 1999; Muthuswamy et al., 1999) . HER-3 is a major docking site for PI3K, and NDF stimulation causes activation of the PI3K pathway and phosphorylation of AKT (Altiok et al., 1999; Liu et al., 1999; Xing et al., 2000) . This ®nding implicates PI3K/AKT in the signaling cascade that results from HER-3 heterodimerization with overexpressed HER-2/ neu receptors in breast cancer cells to promote cell survival and enhanced tumor aggressiveness (Shak, 1999; Huang et al., 2000) .
The signi®cance of AKT expression and activation in human cancer is becoming increasingly evident (Testa and Bellacosa, 2001) . We have reported ampli®cation and overexpression of AKT2 in pancreatic and ovarian cancers (Bellacosa et al., 1995; Cheng et al., 1996; Ruggeri et al., 1998) . In breast tumors, AKT3 over-expression has been reported in estrogen receptornegative breast tumors (Nakatani et al., 1999) , and AKT1 activation has been reported in *40% of breast carcinomas (Sun et al., 2001a) . Moreover, recent data have shown that AKT2 is activated in many breast cancers, and its activation is induced by estrogen receptor a (ERa) via an interaction between ERa and PI3K (Sun et al., 2001b) . Cells with activated AKT2 were found to be estrogen independent and resistant to the anti-hormonal therapeutic agent Tamoxifen (Sun et al., 2001b) , and overexpression of HER-2/neu in breast cancer cells also has been associated with resistance to Tamoxifen (Wright et al., 1992; StaÊ l et al., 2000) .
To determine the relevance of AKT expression in HER-2/neu-expressing tumors and their resistance to stress signals, we initially analysed protein levels of AKT1 and AKT2 in a series of breast cancers for which the HER-2/neu status was known. We found that in tumors with HER-2/neu overexpression and ampli®cation, AKT2 expression was signi®cantly upregulated. In addition, cancers with AKT2 upregulation exhibited increased AKT activity. In vitro studies revealed that overexpression of HER-2/neu results in resistance to stress-induced cell death, which was blocked by speci®c inhibitors of PI3K. This is the ®rst report of a direct correlation between elevated expression of HER-2/neu and overexpression of AKT2. We also demonstrate a link between AKT kinase activation and resistance to stress-induced programmed cell death in HER-2/neu-overexpressing cells.
Results
Upregulation of AKT2 in breast cancer correlates with overexpression of HER-2/neu HER-2/neu-overexpressing breast cancers exhibit increased resistance to some forms of cytotoxic therapy than breast cancers without overexpression of this oncoprotein (Alaoui-Jamali et al., 1997) . Activation of the anti-apoptotic AKT signaling pathway has been found in some HER-2/neu-overexpressing cell lines (Zhou et al., 2000 (Zhou et al., , 2001 . To extend these ®ndings, we tested patient tumor samples for HER-2/neu expression and found a correlation with expression of AKT2, but not AKT1. AKT3 was not tested, since a commercial anti-AKT3 antibody for immunohistochemistry was not available. For this study, we selected tissues from 26 tumors that expressed normal levels of HER-2/neu and 26 tumors with known overexpression of HER-2/ neu (Table 1 and Figure 1a ). Fluorescence in situ hybridization (FISH) analysis showed increased HER-2/neu copy numbers in tumor specimens overexpressing HER-2/neu ( Figure 1b) .
As shown in Table 1 and graphically represented in Figure 1c , AKT2 levels were signi®cantly higher in the HER-2/neu overexpressing group. AKT2 levels varied from a low of 0.01 optical density units (OD) to a high of 2.5. Samples without overexpression of HER-2/neu (level of +1 or less) had AKT2 levels ranging from 0.01 to 0.27 OD. Most samples (25 of 26) with HER-2/neu overexpression (+3) had AKT2 levels Figure 1c ). The tumor tissues available for our study were paran-embedded clinical specimens, and it was not possible to obtain parallel snap-frozen material for in vitro kinase assays. As an alternative, we used a phospho-speci®c, pan-AKT antibody for the immunohistochemical analysis of tumors with and without overexpression of AKT2. The results demonstrated that increased AKT2 expression correlated with increased total AKT activity ( Figure 1d ). AKT2 expression or AKT activity did not show a strong correlation with expression of ER or progesterone receptor (PR).
AKT2 protein is upregulated by ectopic expression of HER-2/neu
To determine if AKT2 can be upregulated by overexpression of HER-2/neu, we used MDA-MB-435 cells and a MDA-MB-435/HER-2 derivative that stably overexpresses HER-2/neu as a result of transfection with a HER-2/neu expression vector (a gift from Dr D Yu, UTMD Anderson Cancer Center, Houston, TX, USA). Western blot analysis revealed that AKT2 expression in MDA-MB-435/HER-2 was approximately 10-fold greater than in the parental cell line AKT upregulation is associated with resistance to hypoxia and correlates with HER-2/neu overexpression
To determine the biological implications of AKT upregulation in connection with overexpression of HER-2/neu, we investigated the growth of MCF7 and MCF7/HER-2 cells under hypoxic conditions in the presence or absence of the PI3K inhibitors wortmannin and LY294002. AKT2 was overexpressed and activated in MDA-MB-435/HER2 cells when compared to parental MDA-MB-435 cells (data not shown). Similarly, AKT2 was overexpressed and activated in MCF7/HER-2 cells compared to parental MCF7 cells. MCF7 cells were sensitive to hypoxia-induced apoptosis, whereas MCF7/HER-2 cells showed increased resistance to programmed cell death induced by hypoxic conditions (Figure 2a,b) . Viability decreased dramatically in the presence of wortmannin and LY294002, indicating that resistance to hypoxia in HER-2/neu-overexpressing cells is associated with activation of the PI3K pathway and that inhibition of this pathway restores sensitivity to hypoxia-induced apoptosis. Resistance to UV-induced cell death was also demonstrated in AU565 cells, which overexpress HER-2/neu. Treatment with LY294002 sensitized AU565 cells to apoptosis induced by UV irradiation (Figure 2c ).
To further con®rm that HER-2/neu and PI3K/AKT signaling play a role in cell survival during stress, we tested the growth of eight breast cancer cell lines under hypoxic conditions. Treatment of cells with 50 mM DFO demonstrated that expression of HER-2/neu correlates with cell survival (Figure 3 ). Breast cancer cells that expressed the highest levels of HER-2/neu (AU565 and BT474) were also the most resistant to hypoxia. These results indicate that HER-2/neu overexpression is associated with cell survival under stress conditions such as hypoxia and UV irradiation and that inhibition of the PI3K/AKT pathway restores cell sensitivity to these conditions.
Activation of AKT occurs in cells that overexpress HER-2/neu
To investigate the functional signi®cance of elevated AKT expression in HER-2/neu overexpressing cells and cancers, we evaluated AKT activity in lysates prepared from the HER-2/neu-overexpressing cell line BT474 (Figure 4 ). This cell line was chosen because of its high level of endogenous HER-2/neu expression and resistance to hypoxia (Figure 3 ). Cells were treated with 150 ng/ml Heregulin or 100 mg/ml Herceptin, a monoclonal antibody directed against the extracellular 
Discussion
Breast and ovarian cancer patients whose tumor cells overexpress HER-2/neu have a poor prognosis. Upregulation of HER-2/neu enhances the metastatic potential of cancer cells and is associated with resistance to various therapeutic regimens (Hancock et al., 1991; Bacus et al., 1994b Bacus et al., , 1996 Bacus et al., , 2000 AlaouiJamali et al., 1997) . The mechanism of HER-2/neumediated resistance in cancer cells is presently unclear. Unlike the other EGF receptors, HER-2/neu has intrinsic tyrosine kinase activity that activates receptor-mediated signaling in the absence of ligand (Bacus et al., 2000) . Ligand binding by EGF receptors induces receptor dimerization and activates PI3K. Although HER-3 signals via PI3K, it is not known whether HER-2/neu homodimers activate PI3K in the absence of extracellular stimulation (Ram et al., 2000; Daly et al., 1999; Altiok et al., 1999; Muthuswamy et al., 1999; Neve et al., 2000) . The PI3K/AKT signaling pathway plays a critical role in apoptosis inhibition, which may contribute to the pathogenesis of cancer, and the development of a hormone-independent phenotype (Cardone et al., 1998; Cantley and Neel, 1999; Datta et al., 1999; Patel et al., 2000) .
To explore the relationship between the PI3K/AKT pathway components and HER-2/neu in breast cancer, we ®rst evaluated AKT1 and AKT2 protein levels in a series of breast cancers in which the HER-2/neu status was known. HER-2/neu-positive tumors exhibited signi®cantly more AKT2 protein than HER-2/neunegative breast cancers (Table 1) . In a recent report using similar antibodies against phospho-AKT (Ser473) and AKT2, AKT2 activation was associated with activation of ERa (Sun et al., 2001b) . These data, together with our ®ndings, suggest that AKT2 expression and activity correlate with potentially important prognostic markers for breast cancer, and that HER-2/neu overexpression and AKT overexpression/activation may result in a hormone-independent phenotype and resistance to anti-hormone therapy such as Tamoxifen.
Another report of immunohistochemistry with phospho-speci®c, pan AKT antibodies found 7 of 10 HER-2/neu-positive tumors that showed strong phospho-AKT staining (Zhou et al., 2000) . We suggest that activation of AKT2 in particular plays an important role in breast tumorigenesis based on the immunohistochemical analyses showing overexpression of AKT2 in the breast tumors. The cytoplasmic staining of phospho-AKT in tumors also is similar to previous reports (Sun et al., 2001a,b) , and overlaps with the staining for AKT2 expression using both polyclonal AKT2 antibodies and a monoclonal AKT2 antibody previously used for the analysis of pancreatic tumors (Ruggeri et al., 1998) . Because the phospho-speci®c, pan-AKT antibodies recognize equivalent phosphorylation sites in AKT1, AKT2 and AKT3, we acknowledge that our positively-stained paran-embedded tumor specimens may have activation of multiple AKT isoforms. Indeed, a recent report has described increased AKT1 kinase activity in 38% (19 out of 50) of snap-frozen breast tumors (Sun et al., 2001a) . We observed overexpression of AKT1 in a signi®cant subset of our tumors, although we did not detect a signi®cant correlation between AKT1 protein expression and HER-2/neu expression. It is likely that any of our specimens that stained positively with the phosphospeci®c, pan-AKT antibody would have activation of any AKT isoform expressed in that tumor, due to shared upstream signaling via PI3K.
We further examined the expression of AKT2 in breast cancer cell lines to elucidate the role of PI3K/ AKT signaling in HER-2/neu-associated resistance to cellular stress. Transfection of breast cancer cells with HER-2/neu resulted in increased expression of AKT1 (data not shown), as well as AKT2, which could re¯ect dierences in cell culture versus in situ conditions. Nevertheless, we show that PI3K/AKT activity is required for resistance to hypoxia-and UV irradiation-induced apoptosis in breast cancer cell lines overexpressing HER-2/neu, and these cells become sensitive to apoptosis-inducing conditions when the PI3K/AKT pathway is blocked by wortmannin or LY294002. Interestingly, activation of AKT has been tested in many of the cell lines in Figure 3 (Zhou et al., 2000) that show a correlation between cellular HER-2/neu expression levels and survival under hypoxic conditions. In these studies, MDA-MB-231, MDA-MB-361 and BT474 had respective low, moderate and high levels of AKT activation under serum-free conditions, indicating that various levels of constitutive AKT activation in the cell lines may directly correlate with levels of HER-2/neu expression.
Several lines of evidence presented here suggest that there is cross talk between the heterodimers of HER-2/neu and HER-3 and the PI3K/AKT pathway. Heregulin, a ligand that causes phosphorylation of HER-2 through heterodimerization with other HER receptors (Holmes et al., 1992; Tzahar et al., 1994; Klapper et al., 1999; Muthuswamy et al., 1999) , stimulated activation of AKT. Moreover, inhibition of the heterodimerization between HER-2 and HER-3 by a monoclonal antibody to HER-2/neu (Herceptin) inhibited AKT activation. Although AKT activation by HER-2/neu overexpression or Heregulin previously has been reported (Shao et al., 1999; Zhou et al., 2000; Ram et al., 2000) , our results further suggest that AKT2 plays a signi®cant role in HER-2/neuoverexpressing breast cancer cells to acquire resistance to cellular stress induced by hormonal therapy, chemotherapeutic agents and/or radiation therapy (Wright et al., 1992; Cobleigh et al., 1999; Shao et al., 1999; Sliwkowski et al., 1999; Patel et al., 2000; StaÊ l et al., 2000; Zhou et al., 2000; Bacus et al., 2001) .
While this report was in preparation, another study demonstrated that HER-2/neu signaling and PI3K/ AKT activation increases the rate of hypoxia-inducible factor 1a (HIF-1a) synthesis (Laughner et al., 2001 ).
HIF-1a activates the transcription of genes important for tumor progression, survival or proliferation (Laughner et al., 2001 ) and thus, may be a downstream target of HER-2/neu and AKT signaling that may mediate resistance of breast cancer cells to cellular stress.
Further evidence in support of the PI3K/AKT pathway as a mediator of HER-2/neu signaling and resistance to apoptotic stress is provided by recent reports showing that AKT phosphorylates p21/WAF in cells overexpressing HER-2/neu to contribute to loss of cell cycle control and decreased therapeutic eectiveness (Asada et al., 1999; Zhou et al., 2001 ). In addition, AKT activation recently has been shown to promote Mdm2 translocation to the nucleus, thereby aecting p53 transcriptional activity and inhibiting of p53 dependent apoptosis (Mayo and Donner, 2001) .
Collectively, these data suggest that cell survival mediated by PI3K/AKT may be a key factor in the cytotoxic resistance of HER-2/neu-overexpressing breast cancers. AKT previously has been shown to act as a survival factor in breast cancer and small cell lung cancer cells (Brognard et al., 2001; Hutchinson et al., 2001) . However, to our knowledge this is the ®rst time a connection has been made between HER-2/neu overexpression and the upregulation of AKT2 expression.
Moreover, this investigation suggests that agents which downregulate AKT2 expression or AKT activation may be of therapeutic value in breast cancers that overexpress HER-2/neu. Although beyond the studies presented here, future investigations are required to de®ne the connection between HER-2/ neu signaling and AKT2 expression/function in mechanistic depth.
Materials and methods

Cells
MCF7 cells were obtained from the Michigan Cancer Foundation (Detroit, MI, USA). A variant of MCF7 cells, MCF7/HER-2, with 5 ± 8-fold elevated expression of HER-2/neu was generated earlier by transfection of MCF7 cells with an ErbB-2 cDNA expression vector (Bacus et al., 2001) . AU-565 cells (Bacus et al., 1992) were obtained from the Cell Culture Laboratory, Navy Biosciences Laboratory (Navy Supply Center, Oakland, CA, USA). MDA-MB-435 and MDA-MB-435/HER-2 were obtained from Dr D Yu (UTMD Anderson Cancer Center, Houston, TX, USA). Cell lines T47D, BT474, MDA-MB-361, MDA-MB-231, and HLB100 were purchased from the ATCC. All of the cells were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 mg/ml) in a humidi®ed incubator with 7% CO 2 at 378C. For the various experiments, exponentially growing cells were inoculated into 150-mm Petri dishes at 1610 6 cells/dish. Cell numbers were determined by hemocytometer chamber counting, and viability was monitored by trypan blue dye exclusion.
Cell treatments
Wortmannin and LY294002 (Calbiochem San Diego, CA, USA) were dissolved in dimethylsulfoxide at a concentration of 1 mM for wortmannin and 50 mM for LY294002 and stored at 7708C. Stock solutions were diluted immediately before use in medium to a ®nal concentration of 1 mM and 50 mM, respectively. Heregulin (Neomarkers, Fremont, CA, USA) was stored as a frozen, concentrated stock solution at 7708C and was diluted in medium immediately prior to use. Herceptin was stored at 7208C at a concentration of 100 mg/ml in 50% glycerol. Where indicated, the cells were exposed to Heregulin (150 ng/ml) or Herceptin (100 mg/ml). Treatment with wortmannin, LY294002, Heregulin or Herceptin were initiated 7 ± 48 h after cell plating. The ®nal concentration of dimethylsulfoxide (maximum 0.25%) in growth medium did not aect cell growth. To simulate hypoxic conditions, cells were also treated with deferoxamine (DFO) for 2 ± 4 days in concentrations ranging from 12 to 50 mM. For UV irradiation, cells were treated for 16 s with 2500 mJoules/cm 2 light energy and harvested after 17 h.
Cell cycle analysis/apoptosis assays DNA content was determined by¯ow cytometry, using an EPICS-753¯ow cytometer as previously described (Dolbeare et al., 1983) . All experiments involving FACS analysis of the cell cycle were repeated at least three times, and representative results are presented. Apoptosis was assessed by DAPI staining to identify apoptotic cells with condensed or fragmented nuclei, and by¯ow cytometry to measure the fraction of subgenomic (sub-G1) cells.
Immunoprecipitation and Western blot analyses
Cells were extracted with lysis buer (50 mM Tris-HCl (pH 7.4), 150 mM sodium chloride, 1 mM EDTA, 1% Nonidet P-40, 1 mM sodium orthovanadate, 1 mM sodium uoride, 1 mM phenylmethylsulfonyl¯uoride, 1 mg/ml pepstatin, 1 mg/ml leupeptin, 1 mg/ml aprotinin). Insoluble material was removed by centrifugation at 48C for 5 min at 6500 g. Protein concentration was determined with a protein assay kit (BioRad, Hercules, CA, USA). Protein lysates (65 ± 75 mg per lane) were subjected to electrophoresis using a BisTris NuPAGE system with 16MOPS running buer (Novex, San Diego, CA, USA), and Western blotted onto Hybond Cextra (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Membranes were blocked with bovine serum albumin or nonfat milk, and incubated with anti-phospho AKT antibody (Dr R Seger, Weizmann Institute, Rehovat, Israel, or Ser 473 antibody from Cell Signaling Technology, Beverly, MA, USA), anti-AKT1 (D-17, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-AKT2 (D-17, Santa Cruz) or anti-PTEN monoclonal antibody (A2B1, Santa Cruz). Detection of horseradish peroxidase-conjugated secondary antibodies was carried out with Renaissance Chemiluminescence Reagent Plus (NEN Life Science, Boston, MA, USA). To detect HER3/HER2 heterocomplexes, anti-HER-3 and anti-HER2 antibodies (NeoMarkers, Fremont, CA, USA) were used for immunoprecipitation and Western blotting, respectively.
The phospho-speci®c, pan-AKT (Ser473) antibodies recognize equivalent phosphorylation sites in all AKT isoforms. Since AKT1, 2, and 3 co-migrate, the individual activated AKT isoforms cannot be distinguished. The isoform speci®city of the anti-AKT1 and anti-AKT2 antibodies was tested by transfecting cells with HA-tagged AKT1 or HAtagged AKT2 expression constructs, immunoprecipitating with anti-HA antibody, and then the isoform speci®city of the antibodies was con®rmed by Western blotting using individual AKT isoform-speci®c antibodies. Similar speci®-city of these antibodies has been reported by other groups (Sun et al., 2001a,b) .
FISH analysis
Fluorescence in situ hybridization (FISH) analysis was performed using the Path Vysion HER-2 DNA Probe Kit (Vysis, Downers Grove, IL, USA), according to the manufacturer's instructions.
Immunohistochemical staining
Cells and tissues were ®xed in 10% neutral buered formalin for 60 min at room temperature, washed with H 2 O, rinsed with Tris-buered saline (0.05 M Tris, 0.15 M NaCl, pH 7.6), and blocked with 10% goat serum (for HER-2) in 0.1% bovine serum albumin/Tris-buered saline for 15 min. Primary antibodies used for immunohistochemistry included AKT1, AKT2, phospho-AKT and HER-2/neu (described above), and a monoclonal AKT2 antibody (Ruggeri et al., 1998) . Primary, secondary and tertiary reagents were incubated for 30, 20, and 15 min, respectively, at 378C and washed with Tris-buered saline between steps. Final detection was achieved using CAS red chromagen (Quantitative Diagnostic Laboratory, Elmhurst, IL, USA).
For paran embedded sections, 4 m sections were placed onto charged slides and dried at 608C for 1 h. The sections were deparanized and hydrated in water. Paran sections were stained for AKT1 and AKT2 as described for the fresh cells, while HER-2/neu staining required antigen retrieval with citrate buer prior to immunostaining. Antigen retrieval was required for immunostaining of estrogen and progesterone receptor, which were visualized with monoclonal antibodies for ER and PR (Clones 6F11 and 636, respectively, Ventana Medical Instruments, Tucson, AR, USA) and a streptavidin peroxidase reaction using DAB as the chromogen (Ventana Medical Instruments). The paran sections were stained for ER and PR according to the manufacturer's instructions using the Ventana Nexus automated staining platform, and ethyl green (Sigma Chemical, St. Louis, MO, USA) was employed as a nuclear counterstain. Phospho-AKT was detected following antigen retrieval using polyclonal antibodies against phosphorylated Ser 473 (Cell Signaling Technology, Beverly, MA, USA) and stained with a streptavidin alkaline phosphatase reaction using Cas Red (Jackson Research Laboratories, West Grove, PA, USA).
Image analysis
HER-2/neu, AKT1, AKT2, phospho-AKT, ER and PR levels were quanti®ed using alkaline phosphatase or peroxidase techniques and microscope-based image analysis of imunohistochemically stained slides (Bacus and Ruby, 1993; Bacus et al., 1994a) . Quanti®cation was by means of a CAS 200 image analyser, as previously described (Bacus et al., 1997) .
